BioInformant

Your Global Leader in Stem Cell Market Research

Home » Archives for Cade Hildreth (CEO) » Page 3

Cord Blood Industry Consolidation Escalates in 2022

By 2 Comments

The global cord blood industry experienced strong growth from the early 1990’s through the late 2000’s, during which time more than 450 cord blood banking companies emerged worldwide. Approximately half of those companies owned their own labs, while the others were marketing entities or sub-contractors of storage space.

Starting about ten years ago, the market suddenly changed course. It entered a period of aggressive consolidation, cutting the global number of cord blood banks by approximately half.

Over the past decade, the cord blood industry has witnessed substantial consolidation, particularly within the United States, Europe, Asia, and Latin America. [Read more…]

What Is An RMAT? List of Publicly Announced RMAT Designations (66)

By 4 Comments

To date, 66 RMAT (Regenerative Medicine Advanced Therapy) designations have been publicly announced. However, the FDA states it has received 187 requests and issued 70, which means that a handful are not yet public knowledge.

Sponsors of cell and gene therapies are eligible to obtain an RMAT designation from the U.S. FDA if their product is intended to treat serious or life-threatening diseases and there is preliminary clinical evidence that it can address unmet medical needs.

Thus far, AlloVir is the only company to receive three RMATs, while six companies (Abeona Therapeutics, Allogene Therapeutics, Athersys, CARsgen Therapeutics, Rocket Pharmaceuticals, and CRISPR Therapeutics) have received two RMAT designations from the U.S. FDA.

[Read more…]

Umoja Biopharma and TreeFrog Therapeutics announce collaboration to address current challenges facing ex vivo allogeneic therapies in immuno-oncology

By Leave a Comment

Partnership combines Umoja’s technologies in gene-edited iPSCs and immune differentiation for persistent anti-tumor activity with TreeFrog Therapeutics’ biomimetic platform for the mass-production of iPSC-derived cell therapies in large-scale bioreactors.

[Read more…]

American Academy of Stem Cell Physicians To Hold Board Examination on June 18, 2022, at 2pm

By Leave a Comment

American Academy of Stem Cell Physicians offers Diplomat And Fellowship Certifications this June 18, 2022, in Miami!

MIAMI, June 6, 2022 – The Board of American Academy of Stem Cell Physicians is the official board certifying body of the American Academy of Stem Cell Physicians. (AASCP). As a nationally recognized academy with a mission to bring like-minded physicians together to increase awareness and education of regenerative medicine, the AASCP is proud to announce the Fellowship and Diplomat certification. [Read more…]

How To Avoid ACL Surgery With Stem Cell Treatment

By 1 Comment

Despite ACL surgeries being more readily available than ever before, torn knee ligaments are still one of the most dreaded injuries for athletes and other active people. The anterior cruciate ligament (ACL) is responsible for stabilizing the knee. If it tears after a sudden wrenching movement, then stability and ease of motion are destroyed. Until recently, ACL surgeries seemed to be the only way for patients to escape the pain, stiffness, and stability loss that comes with an ACL injury.

Fortunately, stem cell treatment may now represent a viable way for some patients to repair torn knee ligaments while avoiding invasive ACL surgeries.

Alternative To ACL Injuries? How Stem Cells Can Help

In this article:

  1. Why Seek an Alternative to ACL Surgery?
  2. How Stem Cell Treatment Addresses an ACL Injury
  3. The Stem Cell Procedure for an ACL Tear
  4. Will Your ACL Injury Respond Well to Stem Cell Treatment?

[Read more…]

BioInformant's World-Class Clients